Natco Pharma

The inspection ran from 17 to 21 August at the Parawada unit. The company describes the observations as procedural and says it expects to address them within the stipulated timeline. The count of observations matters less than the eventual classification: a VAI outcome closes the matter, an OAI outcome restricts new approvals from the site.

Adcock Ingram is a South African pharmaceutical company in which Natco already held a stake. The additional purchase deepens the company's exposure to the South African market and extends its push to earn outside the India and US base.

It will buy 1.96 crore shares at ZAR 92.50 in the wholly owned Natco Pharma South Africa, one of Natco's larger overseas capital commitments.